Rachel Haurwitz

Notable Quotes

Selection of both of Caribou's allogeneic CAR-T cell programs as late-breaking presentations underscores the strength of the safety, efficacy, and durability data and the potential impact these off-the-shelf CAR-T cell therapies can have in addressing urgent patient need. — February 2026, on Tandem Meetings presentation

from Off-the-shelf cancer cell therapy clears major regulatory hurdle toward replacing custom-made treatments · Updated 2 days ago

Stories

Off-the-shelf cancer cell therapy clears major regulatory hurdle toward replacing custom-made treatments

New Capabilities

Leading CB-011 through accelerated FDA pathway

Every approved cancer cell therapy on the market today requires the same costly bottleneck: extracting a patient's own immune cells, engineering them in a lab over weeks, and infusing them back — a process that costs over $400,000 and leaves some patients waiting so long their cancer outpaces the manufacturing. On March 31, 2026, the Food and Drug Administration (FDA) granted accelerated regulatory status to CB-011, the first donor-derived cell therapy engineered to hide from a patient's immune system, after it produced a 92% response rate in a Phase 1 trial for multiple myeloma — a blood cancer that kills roughly 12,000 Americans each year.

Updated 2 days ago

Rachel Haurwitz

Notable Quotes

Stories

Off-the-shelf cancer cell therapy clears major regulatory hurdle toward replacing custom-made treatments

Help us improve Newzino